Current and Potential Therapies Targeting Inflammation in NASH

被引:27
|
作者
Albhaisi, Somaya [1 ]
Noureddin, Mazen [2 ]
机构
[1] Virginia Commonwealth Univ, Dept Internal Med, Richmond, VA 23298 USA
[2] Cedars Sinai Med Ctr, Comprehens Transplant Ctr, Karsh Div Gastroenterol & Hepatol, Los Angeles, CA 90048 USA
来源
FRONTIERS IN ENDOCRINOLOGY | 2021年 / 12卷
关键词
non-alcoholic steatohepatitis; inflammation; treatment; macrophages; lymphocytes; cytokines; hepatocellular injury; oxidative stress; FATTY LIVER-DISEASE; NONALCOHOLIC STEATOHEPATITIS PATIENTS; FARNESOID X RECEPTOR; EXTRACELLULAR VESICLES; S-ADENOSYLMETHIONINE; DIAGNOSTIC-ACCURACY; HEPATIC STEATOSIS; NATURAL-HISTORY; VITAMIN-D; FIBROSIS;
D O I
10.3389/fendo.2021.767314
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Nonalcoholic steatohepatitis (NASH) is the advanced form of nonalcoholic fatty liver disease (NAFLD). It is characterized by hepatic steatosis, inflammation, hepatocellular injury, and fibrosis. Inflammation plays a key role in the progression of NASH and can be provoked by intrahepatic (e.g., lipotoxicity, immune responses, oxidative stress and cell death) and extrahepatic sources (adipose tissue or gut). The identification of triggers of inflammation is central to understanding the mechanisms in NASH development and progression and in designing targeted therapies that can halt or reverse the disease. In this review, we summarize the current and potential therapies targeting inflammation in NASH.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Targeting airway inflammation in asthma - Current and future therapies
    Hanania, Nicola A.
    CHEST, 2008, 133 (04) : 989 - 998
  • [2] Current therapies and new developments in NASH
    Dufour, Jean-Francois
    Anstee, Quentin M.
    Bugianesi, Elisabetta
    Harrison, Stephen
    Loomba, Rohit
    Paradis, Valerie
    Tilg, Herbert
    Wong, Vincent Wai-Sun
    Zelber-sagi, Shira
    GUT, 2022, 71 (10) : 2123 - 2134
  • [3] Current and potential inflammation targeted therapies in head and neck cancer
    Wang, Frederick
    Arun, Pattatheyil
    Friedman, Jay
    Chen, Zhong
    Van Waes, Carter
    CURRENT OPINION IN PHARMACOLOGY, 2009, 9 (04) : 389 - 395
  • [4] Current and future pharmacological therapies for NAFLD/NASH
    Sumida, Yoshio
    Yoneda, Masashi
    JOURNAL OF GASTROENTEROLOGY, 2018, 53 (03) : 362 - 376
  • [5] Current and future pharmacological therapies for NAFLD/NASH
    Yoshio Sumida
    Masashi Yoneda
    Journal of Gastroenterology, 2018, 53 : 362 - 376
  • [6] The molecular basis for current targets of NASH therapies
    Qureshi, Kamran
    Neuschwander-Tetri, Brent A.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (02) : 151 - 161
  • [7] Current treatment paradigms and emerging therapies for NAFLD/NASH
    Raza, Sana
    Rajak, Sangam
    Upadhyay, Aditya
    Tewari, Archana
    Sinha, Rohit Anthony
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2021, 26 (02): : 206 - 237
  • [8] Therapies Targeting Inflammation After Stent Implantation
    Okura, Hiroyuki
    Takagi, Tsutomu
    Yoshida, Kiyoshi
    CURRENT VASCULAR PHARMACOLOGY, 2013, 11 (04) : 399 - 406
  • [9] Therapeutic potential of targeting inflammation
    Hamilton, John A.
    INFLAMMATION RESEARCH, 2013, 62 (07) : 653 - 657
  • [10] Therapeutic potential of targeting inflammation
    John A. Hamilton
    Inflammation Research, 2013, 62 : 653 - 657